29th May 2015: The 12th Annual Alzheimer’s and Parkinson’s Disease (AD/PDTM) Conference took place in Nice, France on 18-22 March, 2015 and saw over 3500 participants from diverse backgrounds coming together to take part in a scientific program covering research, developments, and treatments of AD, PD and related neurological disorders.
One of the highlights of the meeting was Biogen’s Phase Ib study results for Aducanumab (BIIB037), an antibody directed at amyloid plaques. Treatment has seen dose and time dependent reductions in amyloid plaques along with a slowing down of the clinical decline in patients. This is a welcome announcement with few treatments currently available that will slow down the progress of AD.
A Roche symposium presenting on the importance of early diagnosis (“Toward Early Diagnosis in AD: Navigating the road ahead”) included a presentation from Prof. Jeffrey Cummings (Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, USA): “The Early Diagnosis of AD” on the diagnostic criteria for AD, published by the International Working Group and the National Institute on Aging-Alzheimer’s Association. These criteria incorporate both a clinical phenotype and a pathological biomarker supportive of AD, which, along with simple cognitive screening tools that can already be adopted in clinical practice, will facilitate recognition of early clinical symptoms of AD. The abstract for Prof. Cumming’s presentation can be found here). A number of other supported symposia were run at the conference. Details for all these symposia can be found here.